Drug intelligence / Profile preview

NBL-022

Development stage: Preclinical
Lead developer: NovaRock Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NBL-022 is a preclinical-stage bispecific antibody being developed by NovaRock Biotherapeutics for the treatment of inflammatory diseases. It is designed to simultaneously target and inhibit the interleukin-4 receptor (IL4R) and thymic stromal lymphopoietin (TSLP), two critical signaling molecules in the type 2 inflammatory pathway. By blocking both pathways, NBL-022 aims to provide enhanced efficacy in conditions such as severe asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis compared to therapies targeting either pathway alone.

Targets

TSLP (Thymic stromal lymphopoietin)IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on NBL-022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBL-022.

Explore the full profile